CRXT - Clarus Therapeutics reports Q3 results
Clarus Therapeutics (NASDAQ:CRXT): Q3 GAAP EPS of -$0.26. Revenue of $4.28M (+92.8% Y/Y) Press Release
For further details see:
Clarus Therapeutics reports Q3 resultsLink your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Stock Information
| Company Name: | Clarus Therapeutics Holdings Inc. |
| Stock Symbol: | CRXT |
| Market: | OTC |
| Website: | clarustherapeutics.com |
Get CRXT Alerts
News, Short Squeeze, Breakout and More Instantly...